Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on May 11, 2015. The filing discloses the entry into a material definitive agreement involving a new loan facility and the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
- Loan Facility: Total principal amount of up to $15,000,000.
- Initial Drawdown: $10,000,000 drawn on May 11, 2015.
- Remaining Availability: $5,000,000 available upon achieving $15,000,000 in trailing 12-month revenue by May 11, 2016.
- Interest Rate: Fixed at 12.5% per annum.
- Repayment Terms: Interest-only for up to 3 years (reducible to 20 months based on performance), followed by 24 equal monthly installments of principal and interest.
- Fees: Final fee of 5% of aggregate principal; prepayment fee of 5% of prepaid principal.
- Equity Issuance: Warrant to purchase 125,000 shares of common stock at an exercise price of $7.85 per share (10-year term).
- Collateral: Secured by substantially all personal property, rights, and assets of the Company and its subsidiaries, including intellectual property.
Material Changes and Covenants
The filing represents a significant increase in debt obligations and a change in capital structure. The Company is now subject to strict affirmative and negative covenants, including:
- Restrictions on incurring additional indebtedness, mergers, acquisitions, or change of control transactions without consent.
- Prohibitions on paying dividends or repurchasing capital stock.
- Requirements to maintain specific insurance and information delivery standards.
- Events of default include bankruptcy, payment failures, material adverse changes, and breaches of material agreements.
Outlook, Risks, and Management Commentary
Management intends to use the loan proceeds for working capital and general corporate purposes. The filing highlights several risks:
- Liquidity Risk: The interest-only period may be shortened to 20 months if minimum revenue or cash balance requirements are not met, accelerating principal repayment obligations.
- Operational Risk: Failure to achieve the $15,000,000 revenue milestone by May 11, 2016, will prevent access to the remaining $5,000,000 of the facility.
- Dilution Risk: The issuance of the Lender Warrant introduces potential dilution to existing shareholders.
- Asset Encumbrance: Substantially all assets, including intellectual property, are pledged as collateral, limiting future financing flexibility.
Investor Verification Checklist
- Verify the Company's current trailing 12-month revenue to assess the likelihood of drawing the remaining $5,000,000.
- Review the Company's cash balance to determine if it meets the requirements to maintain the 3-year interest-only period.
- Confirm the impact of the 12.5% interest rate and 5% fees on future cash flow projections.
- Assess the valuation impact of the 125,000 warrant shares exercisable at $7.85 relative to the current market price.
- Examine the specific definitions of "Material Adverse Change" and other default triggers in the full Loan Agreement (Exhibit 10.1).